What We Can Learn From Our Patients
December 15th 2014Patient satisfaction data can give practices insight into their operations and make specific, practice-level adjustments accordingly, and with aggregated data we can gain insights into global practice responsiveness and patient perceptions regarding care.
The 340b Drug Discount Program: Oncology's Optical Illusion
November 15th 2013The historical rationale for the 340b program is a good one: indigent patients do need reliable access to prescription drugs, and entities meeting this need should be supported. However, the evolution of the 340b program has strayed widely from its original intent.
The Cost of Cancer Care: Part II
November 15th 2012In Part II, I focus on ideas and specific programs that may slow the growth of spending while, it is hoped, minimizing the impact on what we all want: sustainable access to high-quality therapy and continued innovation. Finally, I will consider another fundamental question: Is current spending worth it?
Ending the Shortage of Generic Oncology Drugs
January 16th 2012Nationally, the number of drug shortages has tripled since 2005. Our county’s hospice agency has experienced shortages of liquid morphine, scopolamine patches, and medications to relieve nausea. Other generic drug shortages in our clinic have included paclitaxel, leucovorin, and doxorubicin. We have had limited ability to order fluorouracil (5-FU) and mitomycin.
Why Physicians Should Become Better Advocates
June 27th 2011Compared with almost any other career, the path to becoming a physician requires a substantial upfront commitment of time, effort and, of course, cost. For oncology specifically, an additional ten years of training after college are required before seeing your first patient independently. In a sense, the day you finish your fellowship, you are already fully “committed.”
A Care Model for the Future: the Oncology Medical Home
June 13th 2011Survival for cancer patients in the United States ranks among the highest in the world.[1] Despite the demonstrated success of the US cancer delivery system, government and private payers are forcing changes to the delivery of and payment model for oncology care.